Drug Information

Drug General Information
Drug ID
D0O4EU
Former ID
DAP001343
Drug Name
Acrivastine
Synonyms
Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
Drug Type
Small molecular drug
Indication Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] Approved [534869]
Therapeutic Class
Antiinflammatory Agents
Company
Pfizer Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C22H24N2O2
Canonical SMILES
CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O
InChI
1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
InChIKey
PWACSDKDOHSSQD-IUTFFREVSA-N
CAS Number
CAS 87848-99-5
PubChem Compound ID
5284514
PubChem Substance ID
7978641, 11039320, 11528790, 12012900, 14827611, 17396918, 39317835, 48415515, 50478506, 57359099, 92719198, 92729786, 93166367, 93309492, 99299401, 103374556, 104178336, 109614385, 113863077, 117544906, 124893773, 126628312, 126651909, 126670557, 127327803, 134338557, 135260703, 137100857, 142971128, 144206566, 162180352, 175268536, 179151367, 185967402, 196106033, 223447811, 223683999, 223704756, 226396645, 252344698
SuperDrug ATC ID
R06AX18
SuperDrug CAS ID
cas=087848995
Target and Pathway
Target(s) Histamine H1 receptor Target Info Antagonist [534875], [537691]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Histamine H1 receptor mediated signaling pathway
Reactome Histamine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
IL-4 Signaling Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 534869Comparative tolerability of second generation antihistamines. Drug Saf. 1999 May;20(5):385-401.
Ref 534875Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52.
Ref 537691Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.